ImmunoGen's new CEO retrenches, axing 65 staffers and looking to thin pipeline
ImmunoGen’s new CEO is done assessing the company, and one of his first acts will involve swinging an ax.
The biotech $IMGN is eliminating 65 jobs, or 17% of the workforce Mark Enyedy inherited when he won the job a few months ago. And he wants to license out some “non-core” B-cell lymphoma program, the company’s second-ranked experimental drug IMGN529 and coltuximab ravtansine, as he vows to pursue a “leaner and more agile” company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.